Study guide

8.2 Interventional and Adjunct Pharmaceuticals

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

8.2 Interventional and Adjunct Pharmaceuticals

Key Takeaways Explain This Topic AI

Pharmacologic MPI stress uses coronary vasodilators (dipyridamole, adenosine, regadenoson) or the inotrope dobutamine; reverse methylxanthine effects with aminophylline and respect caffeine holds

Captopril/enalaprilat unmask renovascular hypertension patterns; furosemide challenges drainage on diuretic renography

HIDA adjuncts: morphine diverts bile into a patent cystic duct; sincalide (CCK) contracts the gallbladder for ejection fraction

Acetazolamide (Diamox®) tests cerebrovascular reserve; insulin-glucose protocols prepare FDG myocardial viability studies

Thyroid pathway adjuncts include Lugol’s/SSKI (stable iodine blockade) and rhTSH (Thyrogen®); PRRT needs antiemetics and amino acids; heparin/ACD support cell labeling

Last updated: August 2026

8.2 Interventional and Adjunct Pharmaceuticals

Quick Answer: Adjuncts are nonradioactive drugs that create the physiology the tracer measures. Memorize what each does , when it is given relative to the RP , key contraindications , and reversal (especially aminophylline after dipyridamole/related stress).

Domain III items often fail candidates on timing and holds , not on isotope half-life.

Pharmacologic Stress for MPI

When patients cannot exercise adequately, pharmacologic coronary hyperemia lets perfusion tracers map flow heterogeneity.

Vasodilators: Dipyridamole, Adenosine, Regadenoson

Agent Mechanism (teaching) Typical administration concept RP timing concept

Dipyridamole Blocks adenosine reuptake → ↑ endogenous adenosine ~ 0.56 mg/kg IV over 4 min (classic) Inject MPI tracer near peak hyperemia (~3–5 min after infusion per protocol)

Adenosine Direct A2A (and other) receptor agonist ~ 140 µg/kg/min IV for ~4–6 min Tracer at mid-to-late infusion while hyperemia maintained

Regadenoson (Lexiscan®) Selective A2A agonist Fixed 0.4 mg IV bolus (~10 s) + flush Tracer typically 10–20 s to ~1 min after injection per protocol

Shared effects: flushing, chest pressure, dyspnea, headache, AV block risk, hypotension. Caffeine and methylxanthines antagonize vasodilators—hold ~12–24 h (protocol; often 24 h taught for caffeine).

Contraindications / cautions (vasodilators): active bronchospasm/severe reactive airway disease (important for nonselective agents; regadenoson is more A2A-selective but still use caution per protocol), high-grade AV block without pacemaker, symptomatic hypotension, acute coronary syndromes per stress-lab rules, recent caffeine/theophylline.

Reversal: Aminophylline

Aminophylline (a theophylline compound) is the classic reversal agent for dipyridamole-related (and often persistent vasodilator) side effects by adenosine-receptor antagonism. It is not the first-line “antidote” concept for dobutamine (use beta blocker). Have it available in the stress lab; dose per ACLS/stress protocol (commonly discussed ~50–250 mg IV slow for persistent symptoms—follow current lab standing orders).

Dobutamine Stress

Dobutamine is a β1-predominant agonist that raises heart rate, contractility, and myocardial oxygen demand—used when vasodilators are contraindicated (e.g., severe asthma) or for selected viability/stress echo crossover protocols.

  • Item Teaching point
  • Infusion Graded increase (e.g., 5 → 10 → 20 → 30 → 40 µg/kg/min) to target HR
  • Tracer timing At peak heart rate / peak stress stage
  • Side effects Palpitations, arrhythmias, hypertension/hypotension, chest pain
  • Reversal Short-acting beta blocker (e.g., esmolol/metoprolol per protocol)—not aminophylline

Atropine may be added if HR fails to rise. Contraindications include severe outflow obstruction and uncontrolled arrhythmias per stress guidelines.

Renal Adjuncts: Captopril, Enalaprilat, Furosemide

Drug Role Timing concept

Captopril (oral) / enalaprilat (IV) ACE inhibition for renovascular hypertension captopril renography—drops GFR in the stenotic kidney via efferent arteriole dilation Give ACEI per protocol before the diagnostic renogram phase; baseline vs post-ACEI comparison

Furosemide (Lasix®) Loop diuretic challenge to distinguish obstructed vs dilated non-obstructed systems F−15, F+0, F+20, etc.—know that washout after diuretic is the interpretive target

Cautions: hypotension after ACEI; hold chronic ACEI only as protocol requires for baseline/post comparison validity; ensure hydration and bladder drainage for renograms. Sulfonamide allergy history may matter for some diuretics—follow site policy.

Hepatobiliary Adjuncts: Morphine and Sincalide (CCK)

Adjunct Mechanism When used

Morphine Contracts sphincter of Oddi , raising common-duct pressure to fill GB if cystic duct patent Nonvisualized GB at ~60 min with adequate hepatic excretion and bowel activity

Sincalide (CCK analog) Stimulates GB contraction Gallbladder ejection fraction ; empty viscous GB after prolonged fasting/TPN before tracer in some protocols

Typical morphine teaching dose is on the order of 0.04 mg/kg IV (max often ~2–4 mg)—confirm protocol. CCK side effects: abdominal cramping, nausea. Opioids given before the study for pain can alter GB filling—document home meds.

Brain, Cardiac Viability, and Thyroid Adjuncts

Drug Study context Key point

Acetazolamide (Diamox®) Brain perfusion reserve (e.g., with Tc-99m HMPAO/ECD) Carbonic anhydrase inhibitor → cerebral vasodilation; compares baseline vs Diamox challenge

Insulin / glucose FDG myocardial viability Metabolic preparation (glucose loading ± insulin) shifts myocardium to glucose utilization so viable hibernating tissue takes FDG

Lugol’s / SSKI Stable iodine Blocks thyroid uptake of free radioiodine/radioiodinated byproducts (e.g., some iodinated RPs, MIBG-related teaching)

Thyrogen® (rhTSH) Thyroid cancer pathway Raises TSH without thyroid hormone withdrawal to stimulate NIS for I-123/I-131 imaging or ablation prep

Diamox cautions: sulfa allergy cross-reactivity concerns, electrolyte shifts, and contraindication in some cirrhosis/severe renal failure settings. Insulin protocols require glucose monitoring to avoid hypoglycemia.

Supportive Meds for Therapy and Labeling

  • Adjunct Use
  • Ondansetron (Zofran®), aprepitant (Emend®) Antiemetics for PRRT, high-dose I-131, AA infusions
  • Amino acid solutions Renal protection during Lutathera (see §8.1)
  • Beta blockers Rate control; reverse dobutamine; sometimes hold before certain stress tests if ordered
  • Heparin / ACD-A Anticoagulation of drawn blood for RBC/WBC labeling to prevent clotting in syringes/kits

Iodinated / other contrast Hybrid CT or correlative angiography—coordinate allergy premed , renal function, and interference with iodine uptake if radioiodine therapy/imaging is imminent

Know when contrast is part of SPECT/CT or Y-90 mapping days and where emergency meds are kept.

Timing Cheat Sheet (RP Relative)

Scenario Adjunct before RP? Adjunct with/after RP?

  • Vasodilator MPI Start pharma stress first Inject tracer at peak hyperemia
  • Dobutamine MPI Escalate infusion first Tracer at target HR
  • Captopril renogram ACEI per protocol before diagnostic phase Tracer after ACEI effect window
  • Diuretic renogram Often tracer first Furosemide at protocol minute
  • Morphine HIDA Tracer first; image ~60 min Morphine if GB still out
  • CCK EF Tracer fills GB CCK after GB visualized
  • Diamox brain Challenge dose timed to perfusion agent Protocol-specific dual-day or split

Exam trap: giving caffeine before adenosine, morphine before a “rule-out acute cholecystitis” without documenting opioids, or aminophylline to reverse dobutamine. Always ask: Does this drug create hyperemia, change GFR, divert bile, block thyroid, protect kidney, or anticoagulate a blood label?